Oral TYK2 Inhibitors Challenge Biologics in Psoriasis

Advances presented at the 2026 American Academy of Dermatology (AAD) meeting highlight a pivotal shift in psoriasis care: oral therapies may finally be approaching the efficacy of biologics. For dermatology clinicians, the emergence of next-generation TYK2 inhibitors—namely, envudeucitinib and zasocitinib—has important implications for patient counseling, treatment selection, and shared decision-making.

The Rise of High-Efficacy Oral TYK2 Inhibitors

Envudeucitinib, developed by Alumis Inc, is a highly selective, allosteric TYK2 inhibitor designed to avoid the broader Janus kinase (JAK) pathways associated with safety concerns. As Andrew Blauvelt, MD, noted, “[Envudeucitinib] has been specifically designed to be an allosteric inhibitor that's specific for TYK2 to avoid blockade of JAK1, JAK2, and JAK3. So we know that's important, because we don't want to have adverse effects associated with classic JAK blockade.”

From a clinical standpoint, this selectivity translates into a reassuring safety profile alongside strong efficacy.¹ In the phase 3 ONWARD trials, envudeucitinib achieved Psoriasis Area and Severity Index (PASI) 75 responses in roughly 75% of patients by week 16, increasing to about 80% by week 24. Even more notable for clinicians is the depth of response: PASI 90 rates approached 60% to 65%, and complete clearance (PASI 100) reached approximately 40% by week 24. Blauvelt emphasized the significance of this benchmark in a recent interview with Dermatology Times, stating, “It’s pretty impressive to see an oral drug with 40% of the patients achieving complete clearance.”

For nurse practitioners and physician assistants, these numbers begin to close the long-standing gap between oral agents and biologics. Historically, oral therapies like apremilast have offered convenience but more modest efficacy. Envudeucitinib challenges that trade-off, offering both high levels of clearance and meaningful symptom relief.

Rapid Symptom Relief: A Patient-Centered Advantage

Equally important is the speed of response with envudeucitinib. Patients reported improvements in itch and quality of life as early as week 2—often before visible skin clearance.¹ In practice, this early symptom relief can significantly improve adherence and patient satisfaction, particularly for those struggling with pruritus, sleep disruption, or high disease burden.

This is a key counseling point: Patients may “feel better” before they “look better,” which can reinforce continuation of therapy during the early treatment phase.

Zasocitinib: Convenience Meets Biologic-Level Efficacy

Zasocitinib (TAK-279), from Takeda, represents another major advancement in the TYK2 class and may be even more impactful from a practical standpoint. Like envudeucitinib, it selectively targets TYK2, but with the added advantage of once-daily dosing—an important consideration for real-world adherence.

In the phase 3 LATITUDE trials, zasocitinib demonstrated similarly strong efficacy.² Approximately 70% of patients achieved clear or almost clear skin (static Physician Global Assessment of Psoriasis [sPGA] 0/1) at week 16, with PASI 90 responses exceeding 50% and reaching over 60% in some cohorts. Complete clearance (PASI 100) was achieved in up to one-third of patients. These results place zasocitinib firmly within the range of biologic-level outcomes.

Melinda Gooderham, MD, underscored what this means for patients to Dermatology Times: “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies.” She added that these findings show “it’s possible for a once-daily pill to deliver rapid, lasting skin clearance,” signaling a potential shift in how clinicians approach first-line systemic therapy.

Durability and Safety in Real-World Use

For clinicians, one of the most compelling aspects of zasocitinib is durability. More than 90% of patients who achieved response maintained it through week 60, addressing a key limitation of earlier oral agents.² Safety findings were also consistent with expectations for TYK2 inhibition, with no new safety signals and mostly mild adverse events such as upper respiratory infections and acne.

Similarly, envudeucitinib demonstrated a favorable safety profile, with no signals for major adverse cardiovascular events, tuberculosis reactivation, or laboratory abnormalities.¹ This reinforces confidence in TYK2 selectivity as a mechanism that balances efficacy with safety.

What This Means for Patient Care

So what do these therapies mean in day-to-day practice?

First, they expand options for patients who are unwilling or unable to use injectable biologics. Needle aversion, travel limitations, and storage concerns are common barriers that can now be addressed with high-efficacy oral alternatives. Second, they may shift the treatment algorithm itself. Rather than stepping from topicals directly to biologics after failure of lower-efficacy orals, clinicians may soon consider TYK2 inhibitors as a preferred oral step with biologic-like outcomes.

Finally, these agents enhance shared decision-making. Patients can now weigh route of administration, convenience, and efficacy without the stark trade-offs that previously existed. For some, a once-daily oral option like zasocitinib may be the deciding factor; for others, the slightly higher complete clearance rates seen with envudeucitinib may be more compelling.

Bottom Line for Clinicians

In practical terms, envudeucitinib may appeal to patients seeking the highest possible likelihood of complete clearance, while zasocitinib offers a balance of strong efficacy with simpler dosing. Both agents represent a broader evolution in psoriasis care—one in which oral therapies are no longer synonymous with compromise.

As these therapies move toward regulatory review, dermatology clinicians should prepare for a changing landscape where highly effective, well-tolerated oral options become central to managing moderate to severe plaque psoriasis.

References

1. Alumis’ envudeucitinib delivers early and robust improvements in skin clearance, quality of life, and psoriasis symptoms in two phase 3 trials, underscoring its potential as a leading oral therapy for plaque psoriasis. News release. Alumis. March 28, 2026. Accessed March 28, 2026. https://investors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-early-and-robust-improvements
2. Takeda’s zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care. News release. Takeda. March 28, 2026. Accessed April 6, 2026. https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/